Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04438057 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
A Phase 2 study of COVID-19, sponsored by Metro Infectious Disease Consultants.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT04438057 is a Phase 2 study of COVID-19 that has completed, run by Metro Infectious Disease Consultants. The registered enrollment target is 103 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04438057, a Phase 2 study of COVID-19, has completed, sponsored by Metro Infectious Disease Consultants.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will provide investigational convalescent plasma for patients infected with the SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation.
Conditions Studied
Interventions
- BIOLOGICAL CCP
Study Locations (1)
Illinois
- Metro Infectious Disease Consultants - Burr Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04438057
The ClinicalTrials.gov registry entry for NCT04438057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Metro Infectious Disease Consultants, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which CCP is the first listed.
NCT04438057 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04438057 about?
NCT04438057 is a clinical study titled "Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19". This study will provide investigational convalescent plasma for patients infected with the SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation.
What is the current status of trial NCT04438057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2020-08-12. Estimated completion is 2021-08-12.
What conditions does trial NCT04438057 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04438057?
The interventions under investigation include: CCP (BIOLOGICAL).
Who is sponsoring clinical trial NCT04438057?
This trial is sponsored by Metro Infectious Disease Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04438057 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.